746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

M. AlHilli,D.S. Miller,J-M. Lee,E.C. Kohn,J. Siedel,J.F. Liu,E. Hopp,A. Miller,J. Chan,K.N. Moore,P. Rose,C. Shah,V. John,K. Matsuo,C. Washington

doi:10.1016/j.annonc.2023.09.1925

746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

M. AlHilli, D.S. Miller + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1925

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2023
Citations: 1

Affiliation: Case Western Reserve University, The University of Texas Southwestern Medical Center, University of Michigan–Ann Arbor, Dana-Farber Cancer Institute, Froedtert Hospital, Medical College of Wisconsin, NRG Oncology, Sutter Medical Center, University of Oklahoma, Northwell Health, University of Southern California

#Standard Of Care Chemotherapy #Durvalumab In Combination + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

Full Text